|Market Size in 2022||Market Forecast in 2030||CAGR (in %)||Base Year|
|USD 11 Billion||USD 15 Billion||7%||2022|
Pet Cancer Therapeutics Market
Pet cancer therapeutics is a new anti-cancer medicine having the capacity to reduce the negative impact of cancer tissues.
The global pet cancer therapeutics market growth can be owing to an increase in the occurrence of pet cancer in developed nations.
According to a study, the global pet cancer therapeutics industry size was $11 billion in 2022 and is projected to reach $15 billion by the end of 2030.
The global pet cancer therapeutics market is anticipated to record a CAGR of nearly 7% from 2023 to 2030.
The Asia-Pacific pet cancer therapeutics industry is set to register the highest CAGR over the forecasting timeline due to the presence of key players in the developing countries of the region.
The global pet cancer therapeutics market is led by players such as Karyopharm Therapeutics, Inc., Zoetis, Oasmia Pharmaceuticals AB, Zenoaq, AB Science, Aratana Therapeutics, Inc., Rhizen Pharmaceuticals SA, Morphogenesis, Inc., Boehringer Ingelheim International GmbH, Regeneus Ltd., and VetDC, Inc.
The pet cancer therapeutics market report covers the geographical market along with a comprehensive competitive landscape analysis. It also includes cash flow analysis, profit ratio analysis, market basket analysis, market attractiveness analysis, sentiment analysis, PESTEL analysis, trend analysis, SWOT analysis, trade area analysis, demand & supply analysis, Porter’s five force analysis, and value chain analysis.